

NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG PROGRAM

DISEASE SITE COMMITTEE MEETING
OPEN AGENDA

Delta Chelsea, Toronto ON
Friday, October 17, 2003 – 8:30 – 11:00 a.m.
Room: Mountbatten Salon A

Chair: Dr. Gerald Batist

8:30 Welcome

Full Trial Reports

IND.140	Phase I	ZD1839, Hormone refractory prostate	Dr. M. Moore
IND.141	Phase I	BAY 43-9006 AML or MDS	Dr. M. Crump
IND.142	Phase II	SARCNU Glioma	Dr. E. Eisenhauer
IND.146	Phase II	SARCNU CRC	Dr. R. Wong
IND.143	Phase II	MG98 Renal	Dr. E. Winqvist
IND.144	Phase I	LY293111 + irinotecan phase I	Dr. M. Moore
IND.147	Phase I	OSI7836	Dr. G. Goss
IND.148	Phase II	OSI774 Endometrium	Dr. A. Oza
IND.149	Phase II	OSI774 Ovary	Dr. H. Hirte

Recently Activated Trials

IND.145	Phase II	ZD6474 Myeloma.....	Dr. M. Kovacs
IND.150	Phase II	PS-341 Mantle Cell Lymphoma	Dr. S. Assouline
IND.152	Phase II	PS-341 Waldenstrom's	Dr. C. Chen
IND.153	Phase I	OGX-011	Dr. K. Chi
IND.154	Phase I	OGX-011 + docetaxel	Dr. K. Chi
IND.157	Phase I/II	OSI-774 + cisplatin head and neck.....	Dr. L. Siu

Updates on new studies/agents (E. Eisenhauer)

Perifosine: IND.155 (Sarcoma) and IND.156 (melanoma)
CCI-779: Endometrium phase II (IND.160)
ALVAC melanoma vaccine: Phase I and randomized phase II trials (IND.158, 159)
RAD001C: breast and glioma studies (IND.162, 163)
Triapine renal cell (IND.161)

11:00 Adjourn

IND COMMITTEE – CLOSED SESSION TO COMMENCE